 | Up a level |
Journal Article
Nitz, U., Gluz, O., Krepe, H., Liedtke, B., Aktas, B., Henschen, S., Pollmanns, A., Krabisch, P., Zuna, I., Shak, S., Thomsseen, C. and Harbeck, N. (2011). First Interim Toxicity Analysis of the Randomized Phase III WSG Plan B Trial Comparing 4xEC-4xDoc Versus 6xTC in Breast Cancer Patients with HER2 Negative Breast Cancer (BC). Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Nitz, U., Gluz, O., Oberhoff, C., Reimer, T., Schumacher, C., Hackmann, J., Warm, M., Uleer, C., Runde, V., Kuemmel, S., Zuna, I. and Harbeck, N. (2011). Adjuvant Chemotherapy with or without Darbepoetin alpha in Node-Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized WSG ARA Plus Trial. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Nitz, U., Gluz, O., Zuna, I., Oberhoff, C., Reimer, T., Schumacher, C., Hackmann, J., Warm, M., Uleer, C., Runde, V., Duennebacke, J., Belzl, N., Augustin, D., Kates, R. E. and Harbeck, N. (2014). Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann. Oncol., 25 (1). S. 75 - 82. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041